AxoGen, Inc. (AXGN) FinancialsAXGNAxoGen, Inc.

Evaluating the bottom line, AxoGen, Inc. maintains a gross margin of 72.67%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -3.09%, while the net margin is -2.17%. These profitability ratios, combined with a Return on Equity (ROE) of -18.21%, provide a clear picture of how effectively AXGN converts its operational activities into shareholder value.

In the context of the broader market, AXGN competes directly with industry leaders such as CDNA and NEOG. With a market capitalization of $2.62B, it holds a leading position in the sector. When comparing efficiency, AXGN's gross margin of 72.67% stands against CDNA's 73.50% and NEOG's 37.59%. Such benchmarking helps identify whether AxoGen, Inc. is trading at a premium or discount relative to its financial performance.

AxoGen has shown significant revenue growth, with Q2 2026 revenue at $69.7 million, up 23% year-over-year. The gross margin is currently at 72.67%, indicating strong profitability potential despite recent challenges.